中国医药导报
中國醫藥導報
중국의약도보
CHINA MEDICAL HERALD
2014年
29期
61-63
,共3页
糖耐量减低%吡格列酮%高胰岛素血症%同型半胱氨酸%内皮素
糖耐量減低%吡格列酮%高胰島素血癥%同型半胱氨痠%內皮素
당내량감저%필격렬동%고이도소혈증%동형반광안산%내피소
Impaired glucose tolerance%Pioglitazone%Hyperinsulinemia%Homocystein%Endothelin
目的：观察吡格列酮对合并高胰岛素血症的糖耐量减低(IGT)患者血浆同型半胱氨酸(Hcy)、内皮素(ET)的影响。方法将60例IGT并高胰岛素血症患者随机分为吡格列酮组和安慰剂组，各30例，分别予盐酸吡格列酮及安慰剂干预治疗15周，测体重指数(BMI)、空腹血糖(FBG)及负荷后血糖(2 h PG)、胰岛素(Ins)、糖化血红蛋白(HbA1c)、胰岛素敏感性指数(ISI)、Hcy、ET等。结果治疗前后比较，安慰剂组差异无统计学意义(P>0.05)；吡格列酮组FBG、2 h PG、HbA1c、空腹胰岛素(FIns)、负荷后2 h胰岛素(2 h Ins)、Hcy、ET水平较治疗前显著下降，ISI显著上升(P<0.05或P<0.01)，两组治疗后比较差异有统计学意义(P<0.05)。结论吡格列酮在增加胰岛素敏感性同时可降低血浆Hcy、ET水平，保护血管内皮功能。
目的：觀察吡格列酮對閤併高胰島素血癥的糖耐量減低(IGT)患者血漿同型半胱氨痠(Hcy)、內皮素(ET)的影響。方法將60例IGT併高胰島素血癥患者隨機分為吡格列酮組和安慰劑組，各30例，分彆予鹽痠吡格列酮及安慰劑榦預治療15週，測體重指數(BMI)、空腹血糖(FBG)及負荷後血糖(2 h PG)、胰島素(Ins)、糖化血紅蛋白(HbA1c)、胰島素敏感性指數(ISI)、Hcy、ET等。結果治療前後比較，安慰劑組差異無統計學意義(P>0.05)；吡格列酮組FBG、2 h PG、HbA1c、空腹胰島素(FIns)、負荷後2 h胰島素(2 h Ins)、Hcy、ET水平較治療前顯著下降，ISI顯著上升(P<0.05或P<0.01)，兩組治療後比較差異有統計學意義(P<0.05)。結論吡格列酮在增加胰島素敏感性同時可降低血漿Hcy、ET水平，保護血管內皮功能。
목적：관찰필격렬동대합병고이도소혈증적당내량감저(IGT)환자혈장동형반광안산(Hcy)、내피소(ET)적영향。방법장60례IGT병고이도소혈증환자수궤분위필격렬동조화안위제조，각30례，분별여염산필격렬동급안위제간예치료15주，측체중지수(BMI)、공복혈당(FBG)급부하후혈당(2 h PG)、이도소(Ins)、당화혈홍단백(HbA1c)、이도소민감성지수(ISI)、Hcy、ET등。결과치료전후비교，안위제조차이무통계학의의(P>0.05)；필격렬동조FBG、2 h PG、HbA1c、공복이도소(FIns)、부하후2 h이도소(2 h Ins)、Hcy、ET수평교치료전현저하강，ISI현저상승(P<0.05혹P<0.01)，량조치료후비교차이유통계학의의(P<0.05)。결론필격렬동재증가이도소민감성동시가강저혈장Hcy、ET수평，보호혈관내피공능。
Objective To observe effect of Pioglitazone on plasma homocystein (Hcy) and endothelin (ET) levels in pa-tients with impaired glucose tolerance (IGT) combined with hyperinsulinemia. Methods 60 IGT patients were divided into two groups randomly: Pioglitazone group (30 cases) and placebo group (30 cases). Placebo were given to placebo group, while Pioglitazone were given to Pioglitazone group for 15 weeks. The body mass index (BMI), fasting and post-prandial plasma glucose (PG), insulin (Ins), hemoglobin A1c (HbA1c), insulin sensitivity index (ISI), plasma Hcy and ET were observed. Results Indexes of placebo group showed no difference between before and after treatment (P> 0.05). The levels of the fasting and postprandial PG and Ins, HbA1c, Hcy and ET dropped obviously in Pioglitazone group com-pared to both the baseline levels and the levels of placebo group at 15 weeks of treatment, the ISI increased markedly in Pioglitazone group (P < 0.05 or P < 0.01), and showed statistical difference between the two groups (P < 0.05). Conclusion Pioglitazone can improve insulin secretion and decrease the levels of Hcy and ET, protect the vascular en-dothelial function.
